Novartis has repeatedly gained recognition in the annual survey for its focus on science and medicine. This year 3,656 survey respondents from biotech and pharma rated companies based on 23 characteristics, including financial strength, research-driven environment, social responsibility and others.
Novartis has a reputation for allowing science and unmet medical need—not sales and market forecasts—to drive research. "We do not look at markets and sales," Dr. Mark C. Fishman, President of Novartis Institutes for BioMedical Research, said in an interview with Science. "I actually forbid review of any of those parameters in any document that I receive from my scientists."